The Study On Evaluating Indices Of Radiotherapy Efficacy For Breast Cancer

[Objective] To explore the predicting values of s-VEGF and s-bFGF levels in the serum as the indicaters of effect radiotherapy. The relationships of s-VEGF and s-bFGF among the groups of pre-radiotherapy, mid-radiotherapy and post-radiotherapy were analyzed. The correlation between s-VEGF, s-bFGF and the traditional clinical pathologic features were respectively studied.[Materials and Method] The sera from 26 healthy female volunteers and 52 breast cancer patients of pre-radiotherapy ,mid-radiotherapy and post-radiotherapy were obtained. The concentrations of VEGF and bFGF in serum were measured with enzyme-linked immunoassay (ELISA).[Results] The concentration of the s-VEGF and s-bFGF in breast cancer patients before radiotherapy were 302.70±30.27pg/ml and 0.92±0.19 pg/m respectively. In the control group, the median of s-VEGF and s-bFGF were 165.22±18.27 pg/ml and 0.86±0.27 pg/ml. There was significant difference in s-VEGF concentrations between breast cancer and the normal control group(P<0.05), but no correlation in s-bFGF (P>0.05). The concentrations of s-VEGF in pre-radiotherapy, mid-radiotherapy and post- radiotherapy of patients with breast cancer were 302.70±30.27pg/ml, 243.96±28.43 pg/ml and 214.45±11.67pg/ml respectively, which was descending gradually. There were significant differences between pre-radiotherapy and mid-radiotherapy, as well as between pre-radiotherapy and post-radiotherapy (P<0.05). No similar result was observed between mid-radiotherapy and post-radiotherapy. The concentrations of the s-bFGF in these three groups were 0.82±0.19pg/ml, 0.81±0.22pg/ml and 0.79±0.17 pg/ml. There was no significant difference among them (P>0.05). The difference of s-VEGF between pre-RT and post-RT in group A and group B were 75.56±12.72pg/ml and 148.45±13.47 pg/m respectively. Compared to group A (I + II+III), significantly decreased level of s-VEGF concentration were observed in groupB (IV) (P<0.05). The levels of s-VEGF of post-RT in ER+PR positive group and ER+PR negative group were not significantly lower than pre-RT(P>0.05). The concentration of s-VEGF of pre-RT between Invasion duct carcinoma group and Invasion lobular carcinoma group were distinguished difference (P<0.05). The concentrations of the s-bFGF between pre-RT and post-RT in group A and group B, ER+PR positive group and ER+PR negative group, Invasion duct carcinoma group and Invasion lobular carcinoma group were no significant decrease(P>0.05).[Conclusion] The study suggested that the levels of the s-VEGF in breast cancer patients are higher than in healthy subjects. s-VEGF may be a useful marker to predict and monitor the effect of radiotherapy . The change of s-VEGF indicated the value of radiotherapy. The change of s-VEGF is closely associated with TNM stage and pathology, but not with ER+PR. The value of s-bFGF was limited and maybe useless in breast cancer patients with radiotherapy.